News

Novartis8d
Novartis completes acquisition of Regulus Therapeutics
We are excited to welcome the talented team at Regulus to Novartis as we continue to build on our pipeline in renal disease with high unmet medical need.” Farabursen is an investigational ...
Novartis (NVS) Acquires Regulus Therapeutics for $1.7 Billion
Novartis AG (NYSE:NVS) is one of the 11 best European stocks to invest in. On June 23, the company confirmed it had completed the acquisition of Regulus Therapeutics. Following the acquisition, the ...
Investing1mon
Regulus Therapeutics Stock Price History - Investing.com
Access Regulus Therapeutics stock price history with daily data, historical prices, all-time highs, and stock chart history. Download and analyze trends easily.
Los Angeles Times2mon
Novartis to buy Regulus Therapeutics for as much as $1.7 billion
Shares in Regulus Therapeutics surged as much as 167% in pre-market trading in New York on Wednesday. The stock has since pared some of those gains to trade at about 131% higher.
Morningstar3mon
Regulus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Recent Updates - Morningstar
About Regulus. Regulus Therapeutics Inc. (Nasdaq: RGLS) is a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs.
Business Insider4y
Regulus Therapeutics to Present Additional Data from its Autosomal Dominant Polycystic Kidney Disease (ADPKD) Program at PKD Connect 2021 - Markets Insider
SAN DIEGO, June 21, 2021 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and develo ...
Nasdaq3y
Regulus Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Lademirsen for Alport Syndrome - Nasdaq
--Regulus Therapeutics Inc., a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs, today announced the completion of enrollment in the ...
FierceBiotech14y
Regulus Therapeutics Promotes Garry E. Menzel, Ph.D., to Chief Operating Officer and Executive Vice President of Finance
LA JOLLA, Calif.--Regulus Therapeutics Inc., a leading microRNA therapeutics company, announced today that it has promoted Garry E. Menzel, Ph.D., to Chief Operating Officer and Executive Vice ...
Longview News-Journal3mon
Regulus Therapeutics Announces Successful Completion of its Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of Farabursen (RGLS8429) for the Treatment of Autosomal ...
SAN DIEGO, March 27, 2025 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ...
Business Insider5y
Regulus Therapeutics Reinitiates Multiple Ascending Dose Study of RGLS4326 for the Treatment of ADPKD - Markets Insider
LA JOLLA, Calif., Feb. 13, 2020 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting ...
Fox 5 San Diego1y
Regulus Therapeutics Advances to Cohort 4 of Phase 1b Multiple-Ascending Dose (MAD) Clinical Trial of RGLS8429 for the Treatment of Autosomal Dominant Polycystic Kidney Disease ...
SAN DIEGO, May 6, 2024 /PRNewswire/ -- Regulus Therapeutics Inc. (Nasdaq: RGLS), a biopharmaceutical company focused on the discovery and development of innovative medicines targeting microRNAs ...
Pharmaceutical Technology on MSN7d
Novartis concludes Regulus Therapeutics acquisition
The transaction was approved by both companies' boards and includes a significant premium over recent stock prices for ...